Compare AAOI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | NAMS |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2013 | N/A |
| Metric | AAOI | NAMS |
|---|---|---|
| Price | $141.60 | $33.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $66.80 | $46.75 |
| AVG Volume (30 Days) | ★ 12.1M | 811.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $119.87 | $17.96 |
| Revenue Next Year | $129.84 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.72 | $15.82 |
| 52 Week High | $155.40 | $42.00 |
| Indicator | AAOI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 53.92 |
| Support Level | $26.00 | $29.73 |
| Resistance Level | N/A | $37.43 |
| Average True Range (ATR) | 14.47 | 1.77 |
| MACD | 3.49 | 0.36 |
| Stochastic Oscillator | 80.14 | 61.07 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.